Colgate‑Palmolive Launches Phase 3 Dentin Hypersensitivity Trial in Brazil

Colgate‑Palmolive (NYSE: CL) has initiated a new material clinical development: the company began recruiting participants for a Phase 3 dentinal hypersensitivity study (registry ID NCT07664592) in Brazil, starting June 29, 2026, with expected completion by September 30, 2026. The trial targets dentinal hypersensitivity and involves 132 participants, reflecting a targeted, late-stage effort within Colgate’s oral-health innovation portfolio.

This move contributes to a robust clinical pipeline in dental and oral health, where Colgate‑Palmolive now lists 106 registered studies including 73 in Phase 3 and 14 in Phase 4. Notably, the number of oral-health-related registrations rose to 24 in the past 12 months from 18 in the preceding year, underscoring a clear acceleration in development activity.

The Brazil study, specifically, is designed to evaluate dentin‑occluding toothpaste technologies aimed at reducing dentinal hypersensitivity. Having entered the active recruitment stage in late June and slated to conclude in September, it represents a near-term milestone with potential implications for product innovation timelines.

While no share‑price movement has been explicitly tied to this development, the launch of a late‑stage clinical trial aligns with Colgate’s broader research strategy and could support future product differentiation in oral care.

Key details at a glance:

• Study phase: Phase 3
• Condition: Dentinal hypersensitivity
• Participants: 132
• Location: Brazil
• Start date: June 29, 2026
• Projected completion: September 30, 2026

This development offers investors insights into the operational execution of Colgate‑Palmolive’s oral‑care innovation engine. As the trial progresses toward its anticipated completion in September, stakeholders may look for updates on interim readouts or subsequent regulatory pathways.

Absent publicized interim results or further announcements, the trial’s start is noteworthy primarily for what it signals about Colgate’s ongoing commitment to late‑stage oral care research and future product pipeline vitality.